Clinical Trials Browser

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04137900 2024-02-05

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Phase 1 Recruiting

499 enrolled

DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Neoplasm Metastasis

NCT05212922 2023-03-20

YH001

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03848611 2020-07-09

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03904719 2020-07-09

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

Phase 2 Unknown

30 enrolled

Thoracic

Small Cell Lung Carcinoma

Clinical Trials

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

YH001

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)